- Report
- November 2026
- 377 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 486 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 288 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 553 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 341 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 380 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 375 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 383 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 476 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 565 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 283 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 141 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 673 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 467 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 466 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 676 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 392 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 553 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 390 Pages
Global
From €5512EUR$5,850USD£4,589GBP
- Report
- November 2026
- 197 Pages
Global
From €5512EUR$5,850USD£4,589GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more